Company Overview

Telix Pharmaceuticals Limited is a clinical-stage and commercial-stage radiopharmaceutical company focused on the development and commercialization of diagnostic and therapeutic products for cancer and rare diseases. The company operates within the nuclear medicine, oncology, and precision medicine industries, leveraging targeted radiation to improve disease detection and treatment. Telix’s business model integrates research, clinical development, manufacturing, and commercialization of radiopharmaceuticals.

The company’s primary revenue driver is its commercial diagnostic imaging products, most notably its prostate cancer imaging agent, alongside a pipeline of therapeutic candidates. Telix serves hospitals, imaging centers, nuclear medicine specialists, and oncology providers, with a strategic focus on unmet clinical needs. Founded in 2015 and headquartered in Australia, Telix has evolved from an R&D-focused biotech into a company with approved products in major global markets, positioning itself as a vertically integrated radiopharmaceutical platform with in-house manufacturing and distribution capabilities.

Business Operations

Telix operates through distinct but integrated business segments centered on radiopharmaceutical diagnostics and radiopharmaceutical therapeutics. Its flagship commercial product, Illuccix®, is a gallium-based prostate cancer imaging agent approved for use with PET imaging, generating the majority of current revenue. The company also develops therapeutic candidates targeting prostate, kidney, brain, and rare cancers using radioisotopes such as lutetium and actinium.

Operations span clinical development, regulatory approval, isotope production, manufacturing, and distribution, with vertically integrated capabilities in key markets. Telix controls proprietary targeting molecules, manufacturing know-how, and a distribution network for short-half-life isotopes. The company maintains subsidiaries and operational entities in the United States, Europe, and Japan, supporting localized manufacturing, regulatory compliance, and commercial execution.

Strategic Position & Investments

Telix’s strategy centers on expanding its commercial diagnostics franchise while advancing a pipeline of late-stage therapeutic radiopharmaceuticals. Growth initiatives include label expansions for existing products, geographic market expansion, and progression of therapeutic candidates into pivotal clinical trials. The company has invested significantly in manufacturing infrastructure, including isotope production and radiopharmacy capabilities, to reduce supply-chain risk and support scalability.

Strategic investments and acquisitions have included targeted purchases of clinical-stage assets, intellectual property, and specialized radiochemistry capabilities to strengthen its development pipeline. Telix’s portfolio includes multiple wholly owned development programs and minority interests in complementary technologies, particularly in targeted alpha therapies and next-generation imaging agents, positioning the company at the intersection of diagnostics and therapeutics (“theranostics”).

Geographic Footprint

Telix operates globally, with corporate headquarters in Australia and primary commercial and operational activities in North America, Europe, and Asia-Pacific. The United States represents the company’s largest commercial market, supported by manufacturing, regulatory, and distribution infrastructure tailored to PET imaging agents.

Internationally, Telix maintains a presence across Europe through subsidiaries and partnerships supporting clinical trials and regulatory approvals, while Japan serves as a strategic market for both diagnostics and therapeutics. The company’s geographic diversification reflects the global nature of nuclear medicine supply chains and provides exposure to multiple regulatory and reimbursement environments.

Leadership & Governance

Telix was founded by industry professionals with experience in biotechnology and nuclear medicine, and its leadership emphasizes clinical rigor, vertical integration, and disciplined capital allocation. The executive team combines expertise in oncology drug development, regulatory strategy, and global commercialization, aligning governance with long-term value creation.

Key executives include:

• Dr. Christian Behrenbruch – Managing Director and Chief Executive Officer
• Dr. Colin Hayward – Chief Medical Officer
• Kevin Richardson – Chief Financial Officer
• Raphaël Ortiz – Chief Commercial Officer
• Dr. David Cade – Chief Technology Officer

The leadership team’s strategic vision focuses on establishing Telix as a global leader in radiopharmaceuticals, balancing near-term commercial execution with sustained investment in innovation and pipeline advancement.